- Document Number:
20240027429
- Appl. No:
18/213417
- Application Filed:
June 23, 2023
- Abstract:
Food allergens and environmental allergens are more readily assessed in vitro than with cumbersome and variable skin tests. Methods for measuring basophil response to allergens are improved when a variety of time points are interrogated and rates of change considered. Interrogation of internal and external markers of basophil activation also improves assessments.
- Claim:
1. A method to prepare samples to aid in determining likelihood of a subject having an allergic reaction against an allergen of interest, the method comprising: stimulating in vitro basophil cells in a first blood sample of the subject by contacting the basophil cells with a selected concentration of the allergen of interest for a first period of time; stimulating basophil cells in vitro in a second blood sample of the subject by contacting the basophil cells with the selected concentration of the allergen of interest for a second period of time; and subjecting the first and second blood samples to an analysis of basophil cell activation and determining the rate of change between the first and second time periods.
- Claim:
2. The method of claim 1 wherein the first and second blood samples are formed by withdrawal and quenching of two aliquots from a common stimulation reaction.
- Claim:
3. The method of claim 1 wherein basophilic cells in additional blood samples are stimulated for additional periods of time.
- Claim:
4. The method of claim 1 wherein basophil cells are stimulated for between three and ten time periods to form from three to ten blood samples.
- Claim:
5. The method of claim 1 wherein the analysis is by flow cytometry.
- Claim:
6. The method of claim 1 wherein the allergen is a food allergen.
- Claim:
7. The method of claim 1 wherein the allergen is an environmental allergen.
- Claim:
8. The method of claim 1 wherein the allergen is peanut protein or peanut protein component.
- Claim:
9. The method of claim 1 wherein the subject has previously been subjected to desensitization immunization therapy with the allergen.
- Claim:
10. A method of treating a subject who is prone to having an allergic reaction against an allergen of interest, the method comprising: stimulating in vitro basophil cells in a first blood sample of the subject by contacting the basophil cells with a selected concentration of the allergen of interest for a first period of time; stimulating basophil cells in vitro in a second blood sample of the subject by contacting the basophil cells with the selected concentration of the allergen of interest for a second period of time; measuring one or more markers of basophil activation in the first and second blood samples; determining a rate of basophil activation by determining a change in amount of the one or more markers between the first and second blood samples; and treating the subject with desensitizing immunotherapy toward the allergen of interest when the rate is determined to be significantly above negative control values.
- Claim:
11. The method of claim 10 wherein the first and second blood samples are formed by withdrawal and quenching of two aliquots from a common stimulation reaction.
- Claim:
12. The method of claim 10 wherein basophilic cells in additional blood samples of the subject are stimulated for additional periods of time.
- Claim:
13. The method of claim 12 wherein basophil cells are stimulated for between three and ten time periods.
- Claim:
14. The method of claim 10 wherein the one or more markers are intracellular phosphorylated proteins.
- Claim:
15. The method of claim 10 wherein the one or more markers are cell surface markers.
- Claim:
16. The method of claim 10 wherein the one or more markers comprise at least one cell surface marker selected from the group consisting of CD203c, MRGPRX2 and CD63.
- Claim:
17. The method of claim 14 wherein the one or more intracellular phosphorylated proteins comprise at least one selected from the group consisting of phospho-Lyn, phospho-Fyn, phospho AKT, phospho S6, phospho-IgE-receptor, and combinations thereof.
- Claim:
18. The method of claim 10 wherein at least one cell surface marker and once intracellular phosphorylated protein are measured in the first and second blood sample.
- Claim:
19. The method of claim 10 wherein the step of measuring employs one or more antibodies which specifically bind to the one or more markers of basophil activation.
- Claim:
20. The method of claim 10 wherein the step of measuring employs flow cytometry.
- Claim:
21. The method of claim 10 wherein the allergen of interest is a food allergen.
- Claim:
22. The method of claim 10 wherein the allergen of interest is an environmental allergen.
- Claim:
23. The method of claim 10 wherein the allergen of interest is peanut protein.
- Claim:
24. The method of claim 10 wherein the subject has previously been subjected to desensitization immunization therapy.
- Claim:
25. A set of assay samples to aid in determining likelihood of a subject having an allergic reaction against an allergen of interest, the set comprising: a plurality of assay samples comprising at least a first and a second blood sample formed by stimulating in vitro basophil cells in a first blood sample of the subject by contacting the basophil cells with a selected concentration of the allergen of interest for a first period of time and by stimulating basophil cells in vitro in a second blood sample of the subject by contacting the basophil cells with the selected concentration of the allergen of interest for a second period of time; wherein the plurality of assay samples are suitable for measuring one or more markers of basophil activation in the blood samples whereby a rate of basophil activation can be determined by determining a change in amount of the one or more markers between any of the blood samples.
- Claim:
26. The set of claim 25 wherein the first and second blood samples are formed by withdrawal and quenching of two aliquots from a common stimulation reaction.
- Claim:
27. The set of claim 25 wherein basophilic cells in additional blood samples are stimulated for additional periods of time.
- Claim:
28. The set of claim 25 wherein basophil cells in three to ten assay samples are stimulated for three to ten time periods.
- Claim:
29. The set of claim 25 wherein the allergen of interest is a food allergen.
- Claim:
30. The set of claim 25 wherein the allergen of interest is an environmental allergen.
- Claim:
31. The set of claim 25 wherein the allergen of interest is peanut protein.
- Claim:
32. The set of claim 25 wherein the subject has previously been subjected to desensitization immunization therapy.
- Claim:
33. A kit to aid in determining likelihood of a subject having an allergic reaction against an allergen of interest, the method comprising: a plurality of tubes for holding at least a first and a second blood sample of the subject in which basophil cells will be stimulated by contacting the basophil cells with a selected concentration of the allergen of interest; the allergen of interest at a predetermined amount in separate packages to be added to the at least first and second blood samples; and a quenching agent for stopping the stimulation of basophil cells at a predetermined amount in separate packages to be added to the at least first and second blood samples.
- Claim:
34. The kit of claim 33 further comprising: a timer for measuring basophil cell stimulation times for the at least first and second blood samples.
- Claim:
35. The kit of claim 33 further comprising: a plurality of timers for predetermined basophil cell stimulation times for the at least first and second blood samples.
- Claim:
36. The kit of claim 33 further comprising: at least one antibody specific for a basophil activation marker.
- Claim:
37. The kit of claim 33 further comprising: at least one antibody specific for a basophil activation marker, wherein the antibody is attached to a fluorescent moiety.
- Claim:
38. The kit of claim 33 further comprising: a plurality of antibodies, wherein each antibody is specific for a basophil activation marker, wherein each antibody is attached to a different fluorescent moiety.
- Claim:
39. A method to aid in determining likelihood of a subject having an allergic reaction against an allergen of interest, the method comprising: stimulating in vitro basophil cells in a first blood sample of the subject by contacting the basophil cells with a selected concentration of the allergen of interest for a first period of time; stimulating basophil cells in vitro in a second blood sample of the subject by contacting the basophil cells with the selected concentration of the allergen of interest for a second period of time; measuring one or more markers of basophil activation in the first and second blood samples; and determining a rate of basophil activation by determining a change in amount of the one or more markers between the first and second blood samples.
- Claim:
40. The method of claim 39 wherein the first and second blood samples are formed by withdrawal and quenching of two aliquots from a common stimulation reaction.
- Claim:
41. The method of claim 39 wherein basophilic cells in additional blood samples are stimulated for additional periods of time.
- Claim:
42. The method of claim 39 wherein basophil cells in three to ten blood samples are stimulated for three to ten time periods, respectively.
- Claim:
43. The method of claim 39 wherein the one or more markers are intracellular phosphorylated proteins.
- Claim:
44. The method of claim 39 wherein the one or more markers are cell surface markers.
- Claim:
45. The method of claim 39 wherein the one or more markers comprise at least one cell surface marker selected from the group consisting of CD203c, MRGPRX2 and CD63.
- Claim:
46. The method of claim 43 wherein the one or more intracellular phosphorylated proteins comprise at least one selected from the group consisting of phospho-Lyn, phospho-Fyn, phospho-IgE-receptor, and combinations thereof.
- Claim:
47. The method of claim 39 wherein antibodies which specifically bind to at least one cell surface marker and at least one intracellular phosphorylated protein are contacted with the first and second blood sample.
- Claim:
48. The method of claim 39 wherein the step of measuring employs one or more antibodies which specifically bind to the one or more markers of basophil activation.
- Claim:
49. The method of claim 39 wherein the step of measuring employs flow cytometry.
- Claim:
50. The method of claim 39 wherein the allergen of interest is a food allergen.
- Claim:
51. The method of claim 39 wherein the allergen of interest is an environmental allergen.
- Claim:
52. The method of claim 39 wherein the allergen of interest is peanut protein.
- Claim:
53. The method of claim 39 wherein the subject has previously been subjected to desensitization immunization therapy.
- Claim:
54. The method of claim 39 wherein the subject is recommended for desensitization therapy on the basis of the determined rate of basophil activation.
- Claim:
55. The method of claim 8 wherein the allergen is peanut protein component and the peanut protein component is selected from the group consisting of: Arah1, Arah2, Arah6, Arah7, AraH8 and Arah10.
- Current International Class:
01; 01; 01
- Accession Number:
edspap.20240027429
Processing Request
No Comments.